Compliance Is Not Waste: Reading Quality Through Lean and the Theory of Constraints

There is a conversation that happens, in various forms, in nearly every manufacturing organization I have observed over twenty-five years in this industry. It happens in budget reviews, in operational excellence steering committees, in the hallway outside a QA office, and — most damagingly — in the unexpressed assumptions that shape how an organization is actually structured and run.…

http://investigationsquality.com/2026/03/28/compliance-is-not-waste-reading-quality-through-lean-and-the-theory-of-constraints/

The Theory of Constraints: A Cornerstone for Advanced Quality Systems and Organizational Maturity

A familiar scene exists across every pharmaceutical manufacturing site I've ever seen, lot disposition cycle times are a struggle. While management instinctively pushes for "optimization everywhere," the quality department remains overwhelmed and becomes the weakest link in an otherwise robust chain. This scenario illustrates perfectly why understanding and applying the…

http://investigationsquality.com/2026/03/14/the-theory-of-constraints-a-cornerstone-for-advanced-quality-systems-and-organizational-maturity/

Environmental Monitoring as a Falsifiable Story: Trending, Investigation, and the Illusion of Control

Environmental monitoring (EM) is not a hygiene check. It is a story we tell ourselves about whether our contamination control strategy actually works. On paper, EM is straightforward: pick locations, define limits, collect samples, trend the data, investigate excursions. In practice, it sits at the messy intersection of microbiology, human behavior, facility design,…

http://investigationsquality.com/2026/03/08/environmental-monitoring-as-a-falsifiable-story-trending-investigation-and-the-illusion-of-control/

The Annex 15 Revision Is Coming: What It Means for Validation, Control Strategy, and Industry Maturity

On January 19, 2026, the EMA GMP/GDP Inspectors Working Group and PIC/S published a concept paper proposing a targeted revision of EU GMP Annex 15—Qualification and Validation. The public consultation opened on February 9 and runs through April 9, 2026. If you work in active substance manufacturing, or if your drug product quality depends on active substance…

http://investigationsquality.com/2026/03/06/the-annex-15-revision-is-coming-what-it-means-for-validation-control-strategy-and-industry-maturity/

Dear Raz: Building Technical Depth from a Compliance Foundation — A Certification Roadmap for Pharma Professionals

A Reader Writes In A long-time reader of this blog, Raz, recently left a comment that I think resonates with a lot of people in our industry: "As a compliance lead with 10+ years of experience in pharma (API sites, greenfield) but lacking a technical background, what would you suggest to be the best courses / trainings for proper certificates?"

http://investigationsquality.com/2026/03/01/dear-raz-building-technical-depth-from-a-compliance-foundation-a-certification-roadmap-for-pharma-professionals/

The Kafkaesque Quality System: Escaping the Bureaucratic Trap

On the morning of his thirtieth birthday, Josef K. is arrested. He doesn't know what crime he's accused of committing. The arresting officers can't tell him. His neighbors assure him the authorities must have good reasons, though they don't know what those reasons are. When he seeks answers, he's directed to a court that meets in tenement attics, staffed by officials whose actions are never explained but…

http://investigationsquality.com/2026/02/20/the-kafkaesque-quality-system-escaping-the-bureaucratic-trap/

An Apology

I am, by temperament, an intellectual magpie. I pick up ideas, frameworks, and images from papers, talks, conference slides, and conversations, and then carry them around in my head until they re-emerge—sometimes polished, sometimes altered, and, in this case, without the clear lineage they deserve. That tendency serves me well as a writer and quality professional, but it also comes with a responsibility to keep better track of where things come from.

http://investigationsquality.com/2026/02/15/an-apology/

The Molecule That Changed Everything: How Insulin Rewired Drug Manufacturing and Regulatory Thinking

There's a tendency in our industry to talk about "small molecules versus biologics" as if we woke up one morning and the world had simply divided itself into two neat categories. But the truth is more interesting—and more instructive—than that. The dividing line was drawn by one molecule in particular: insulin. And the story of how insulin moved from animal extraction…

http://investigationsquality.com/2026/02/08/the-molecule-that-changed-everything-how-insulin-rewired-drug-manufacturing-and-regulatory-thinking/

The Product Lifecycle Management Document: Pharmaceutical Quality’s Central Repository for Managing Post-Approval Reality

Pharmaceutical regulatory frameworks have evolved substantially over the past two decades, moving from fixed-approval models—where products remained frozen in approved specifications after authorization—toward dynamic lifecycle management approaches that acknowledge manufacturing reality. Products don't remain static across their commercial life.…

http://investigationsquality.com/2026/02/07/the-product-lifecycle-management-document-pharmaceutical-qualitys-central-repository-for-managing-post-approval-reality/

Mentorship as Missing Infrastructure in Quality Culture

The gap between quality-as-imagined and quality-as-done doesn't emerge from inadequate procedures or insufficient training budgets. It emerges from a fundamental failure to transfer the reasoning, judgment, and adaptive capacity that expert quality professionals deploy every day but rarely articulate explicitly. This knowledge—how to navigate the tension between regulatory compliance and operational reality, how…

http://investigationsquality.com/2026/01/10/mentorship-as-missing-infrastructure-in-quality-culture/